Related references
Note: Only part of the references are listed.First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
Cutaneous adverse effects of the immune checkpoint inhibitors
Lindsey K. Collins et al.
CURRENT PROBLEMS IN CANCER (2017)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
G. Gibney et al.
EUROPEAN JOURNAL OF CANCER (2015)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine
Zuzana Berrong et al.
Journal for ImmunoTherapy of Cancer (2014)
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate
Alexander J. Muller et al.
CANCER RESEARCH (2010)
Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease
David Favre et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
Jonathan R. Brody et al.
CELL CYCLE (2009)
Interferon-γ-Responsive Nonhematopoietic Cells Regulate the Immune Response to Mycobacterium tuberculosis
Ludovic Desvignes et al.
IMMUNITY (2009)
Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival
Kazuhiko Ino et al.
CLINICAL CANCER RESEARCH (2008)
High expression of indoleamine 2,3-dioxygenase gene in prostate cancer
Chantal Feder-Mengus et al.
EUROPEAN JOURNAL OF CANCER (2008)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
M. E.D. Chamuleau et al.
HAEMATOLOGICA (2008)
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection
Agnes Witkiewicz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase
T. Banerjee et al.
ONCOGENE (2008)
Mechanisms of local immunosuppression in cutaneous melanoma
M. E. Polak et al.
BRITISH JOURNAL OF CANCER (2007)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
K. Ino et al.
BRITISH JOURNAL OF CANCER (2006)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer
A Huang et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
